section name header

Pronunciation ⬇

MI-gli-tole

Classifications ⬆ ⬇

Therapeutic Classification: antidiabetics

Pharmacologic Classification: alpha glucosidase inhibitors

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Lowers blood glucose by inhibiting the enzyme alpha-glucosidase in the GI tract, resulting in delayed glucose absorption.
Therapeutic effects:
  • Lowering of blood glucose in diabetic patients, especially postprandial hyperglycemia.

Pharmacokinetics ⬆ ⬇

Absorption: Completely absorbed at lower doses (25 mg); 50–70% absorbed at higher doses (100 mg).

Distribution: Distributes primarily into extracellular fluid; small amounts enter breast milk.

Metabolism/Excretion: Not metabolized; action is primarily local in the GI tract; amounts that are absorbed are excreted mostly unchanged in urine.

Half-Life: 2 hr.

Time/Action Profile ⬆ ⬇

(effect on glucose absorption)

ROUTEONSETPEAKDURATION
POrapidwithin 1 hrunknown



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

GI: abdominal pain, diarrhea, flatulence

Hemat: low serum iron

Interactions ⬆ ⬇

Drug-drug:

Drug-Food:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Toxicity and Overdose:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Glyset